Unique ID issued by UMIN | UMIN000029324 |
---|---|
Receipt number | R000033119 |
Scientific Title | Double-blind placebo-controlled clinical trial of thalidomide for chronic granulomatous disease-associated colitis |
Date of disclosure of the study information | 2017/10/01 |
Last modified on | 2025/04/03 11:14:52 |
Double-blind placebo-controlled clinical trial of thalidomide for chronic granulomatous disease-associated colitis
Clinical trial of thalidomide for CGD colitis
Double-blind placebo-controlled clinical trial of thalidomide for chronic granulomatous disease-associated colitis
Clinical trial of thalidomide for CGD colitis
Japan |
Chronic granulomatous disease associated colitis
Medicine in general | Gastroenterology | Clinical immunology |
Others
NO
We assess a safety and efficacy of thalidomide for chronic granulomatous disease-associated colitis.
Safety,Efficacy
Ratio of subjects decreasing more than 20 points of Pediatric ulcerative colitis activity index (PUCAI) or being less than 10 of PUCAI score at the end of double-blind trial
1) Ratio of subjects being less than 10 of PUCAI score at the end of double-blind trial
2) Ratio of subjects decreasing more than one point of physician's global assessment (PGA) at the end of double-blind trial
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Placebo
2
Treatment
Medicine |
Oral administration of thalidomide (1.5-3mg/kg), once a day
Oral administration of placebo (1.5-3mg/kg), once a day
1 | years-old | <= |
Not applicable |
Male and Female
1) Diagnosis of CGD colitis, ages over one year
2) Moderate CGD colitis (35 /<= PUCAI < 65), or Mild CGD colitis (10 /<= PUCAI <35) carrying bloody stool or over six times of defecation at the onset or relapse
3) Signed informed consent form agreeing to the clinical trial participation
4) Informed consent to compliance rules including administration of investigational agent and contraception
1) Patients allergic to the drug ingredients
2) Patients with HIV infection
3) Cancer except granuloma
4) Macrophage activating syndrome
5) Any mental problem
6) Pregnant or breast-feeding woman
7) Taking thalidomide or having a history of thalidomide administration
8) Oral, intravenous, or enema administration of steroid within four weeks of providing informed consent
9) Administration of immunomodulator within eight weeks of providing informed consent
10) A history of any biological agent administration
11) Miner who do not have guardian for appropriate administration of investigational agent
12) In certain circumstances that the researchers determined it was not suitable for the research
8
1st name | Toshinao |
Middle name | |
Last name | Kawai |
National Center for Child Heath and Development
Division of Immunology
157-8535
2-10-1 Okura, Setagaya-ku, Tokyo, Japan
03-3416-0181
kawai-t@ncchd.go.jp
1st name | Mayumi |
Middle name | |
Last name | Sako |
National Center for Child Heath and Development
Division of Child Health and Development
157-8535
2-10-1 Okura, Setagaya-ku, Tokyo, Japan
03-3416-0181
sako-m@ncchd.go.jp
National Center for Child Heath and Development
Japan Agency for Medical Research and Development
Japanese Governmental office
National Center for Child Heath and Development
2-10-1 Okura, Setagaya-ku, Tokyo, Japan
03-3416-0181
seiiku-chiken@ncchd.go.jp
NO
国立研究開発法人国立成育医療研究センター(東京都)
2017 | Year | 10 | Month | 01 | Day |
Unpublished
Completed
2017 | Year | 09 | Month | 01 | Day |
2017 | Year | 06 | Month | 15 | Day |
2017 | Year | 09 | Month | 28 | Day |
2022 | Year | 03 | Month | 31 | Day |
2017 | Year | 09 | Month | 28 | Day |
2025 | Year | 04 | Month | 03 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000033119